Evidence map›Paper›PMID 33080073›Full record

ArticleJournal of clinical laboratory analysis2021

Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes.

Yanli Yang, Jun Li, Yinghua Geng, Lin Liu, Dianming Li

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yanli YangDepartment of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu City, China.
Jun LiDepartment of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu City, China.
Yinghua GengDepartment of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu City, China.
Lin LiuDepartment of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu City, China.
Dianming LiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.ORCID https://orcid.org/0000-0002-1279-1319
First Affiliated Hospital of Bengbu Medical College · CN

Funding

Key Natural Science Research Projects of Anhui Education Department KJ2019A0375
6 · The paper itself

Abstract

backgroundMyelodysplastic syndrome (MDS) is a heterogeneous clonal disease originated from hematopoietic stem cells. Epigenetic studies had demonstrated that DNA methylation and histone acetylation were abnormal in MDS. Azacitidine is an effective drug in the treatment of demethylation.

methodsRT-PCR was performed to determine GADD45γ in 15 MDS clinical samples. Myelodysplastic syndrome cell lines SKM-1 and HS-5 were transfected with GADD45γ eukaryotic expression vector and/or GADD45γ shRNA interference plasmid, and treated with azacitidine. Proliferation and apoptosis were examined by CCK-8 and Western blot analysis to confirm the function role of GADD45γ and azacitidine. The methylation level of GADD45γ gene was detected by bisulfite conversion and PCR.

resultsThis study found that GADD45γ gene was down-expressed in MDS patients' bone marrow and MDS cell lines, and the down-regulation of GADD45γ in MDS could inhibit MDS cell apoptosis and promote proliferation. Azacitidine, a demethylation drug, could restore the expression of GADD45γ in MDS cells and inhibit the proliferation of MDS cells by inducing apoptosis, which was related to prognosis and transformation.

conclusionThis study indicated that GADD45γ was expected to become a new target of MDS-targeted therapy. The findings of this study provided a new direction for the research and development of new MDS clinical drugs, and gave a new idea for the development of MDS demethylation drug to realize precise treatment.

Indexed as

ApoptosisAzacitidineBone Marrow CellsCell Cycle ProteinsCell LineCell ProliferationDNA MethylationGADD45 ProteinsGene ExpressionGenetic TherapyHumansMyelodysplastic SyndromesAzacitidineCell Cycle ProteinsGADD45A protein, humanGADD45 ProteinsazacitidineGADD45γMDS

Identifiers

PMID33080073
PMCPMC7891504
OpenAlexW3094574324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.